Global Liver Diseases Treatment Market to Reach $37.9 Billion by 2030
The global market for Liver Diseases Treatment estimated at US$17.1 Billion in the year 2022, is projected to reach a revised size of US$37.9 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2022-2030. Anti-Rejection Drugs/Immunosupressants, one of the segments analyzed in the report, is projected to record 11% CAGR and reach US$6.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chemotherapy Drugs segment is readjusted to a revised 11.6% CAGR for the next 8-year period.The U.S. Market is Estimated at $4.5 Billion, While China is Forecast to Grow at 13.8% CAGR
The Liver Diseases Treatment market in the U.S. is estimated at US$4.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$8.8 Billion by the year 2030 trailing a CAGR of 13.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.1% and 8.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.Select Competitors (Total 41 Featured) -
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Johnson & Johnson Pvt., Ltd.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
- Sanofi SA
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Liver Diseases Treatment - Global Key Competitors Percentage Market Share in 2021 (E)
- Impact of Covid-19 and a Looming Global Recession
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2021 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Liver Diseases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Anti-Rejection Drugs/Immunosupressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Anti-Rejection Drugs/Immunosupressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Anti-Rejection Drugs/Immunosupressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Chemotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Chemotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Chemotherapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Targeted therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Targeted therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Targeted therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 18: World 16-Year Perspective for Anti-Viral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Iimmunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Iimmunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 21: World 16-Year Perspective for Iimmunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 24: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 25: World Liver Diseases Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 26: USA Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: USA 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: Canada Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: Canada 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- JAPAN
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 32: Japan Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Japan Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Japan 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- CHINA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 35: China Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: China Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: China 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- EUROPE
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 38: Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 39: Europe Historic Review for Liver Diseases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Europe 16-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 41: Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Europe Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Europe 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- FRANCE
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 44: France Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: France Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: France 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- GERMANY
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 47: Germany Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: Germany Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: Germany 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- ITALY
- Table 50: Italy Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Italy Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Italy 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 53: UK Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: UK Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: UK 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- SPAIN
- Table 56: Spain Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Spain Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Spain 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- RUSSIA
- Table 59: Russia Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Russia Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Russia 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 62: Rest of Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Rest of Europe Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Rest of Europe 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 66: Asia-Pacific Historic Review for Liver Diseases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: Asia-Pacific 16-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 68: Asia-Pacific Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Asia-Pacific Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Asia-Pacific 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2023 & 2030
- AUSTRALIA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
- INDIA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
- SOUTH KOREA
- REST OF ASIA-PACIFIC
- LATIN AMERICA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
- ARGENTINA
- BRAZIL
- MEXICO
- REST OF LATIN AMERICA
- MIDDLE EAST
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
- IRAN
- ISRAEL
- SAUDI ARABIA
- UNITED ARAB EMIRATES
- REST OF MIDDLE EAST
- AFRICA
- Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Johnson & Johnson Pvt., Ltd.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
- Sanofi SA
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 194 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 17.1 Billion |
Forecasted Market Value ( USD | $ 37.9 Billion |
Compound Annual Growth Rate | 10.5% |
Regions Covered | Global |